• Potent Pyrimidine Inhibitors Target TSSK2 for Male Contracep

  2026-06-13

  This study identifies the first sub-100 nM pyrimidine and pyrrolopyrimidine inhibitors of testis-specific serine/threonine kinase 2 (TSSK2), a promising target for reversible male contraception. The findings establish new benchmarks for potency and selectivity in kinase inhibitor design, informing future contraceptive and kinase-targeted drug development.

• Morin: Applied Protocols and Innovations in Disease Modeling

  2026-06-12

  Morin, a high-purity natural flavonoid, stands apart for its dual role as a mitochondrial modulator and fluorescent probe. This guide translates breakthrough mechanistic findings into actionable workflows, troubleshooting, and advanced applications for metabolic disease, kidney injury, and ion detection research.

• Axitinib (AG 013736): Precision Tools for Angiogenesis Assay

  2026-06-12

  Axitinib (AG 013736) delivers unparalleled selectivity and reproducibility in angiogenesis inhibition and tumor xenograft research. This guide translates the latest in vitro evaluation frameworks and workflow enhancements into actionable protocols, arming cancer biology labs with advanced troubleshooting and data interpretation strategies.

• Eclipta–Hordeum Extract Delays Precocious Puberty in Danazol

  2026-06-11

  This study demonstrates that an Eclipta prostrata and Hordeum vulgare extract complex (EHEC) can effectively delay precocious puberty onset in rat models induced by Danazol or high-fat diet. By modulating the hypothalamic–pituitary–gonadal axis and attenuating GnRH expression, EHEC offers promising evidence for natural alternatives to current pharmacological interventions.

• HyperScribe Co-transcription mRNA Synthesis Kit Plus: Applie

  2026-06-11

  The HyperScribe Co-transcription mRNA Synthesis Kit Plus unlocks robust, high-yield ARCA-capped mRNA production with integrated poly(A) tails, streamlining demanding applications from RNA vaccine design to RNAi. Explore optimized protocols, advanced use-cases, and expert troubleshooting that set this kit apart in translational research.

• Ruxolitinib (INCB018424): Advanced Workflows in JAK-STAT Res

  2026-06-10

  Ruxolitinib (INCB018424) empowers high-resolution dissection of JAK-STAT signaling and immune remodeling in myeloproliferative disorder research. This guide translates recent breakthroughs in spectral flow cytometry and combination therapy into actionable protocols and troubleshooting strategies for advanced immunoprofiling and oncogenic JAK2 fusion studies.

• Anlotinib Hydrochloride: Optimizing Multi-Target Angiogenesi

  2026-06-10

  Anlotinib hydrochloride is revolutionizing angiogenesis and cancer research as a selective, high-potency multi-target tyrosine kinase inhibitor. This guide translates key preclinical breakthroughs into actionable protocols, advanced workflows, and troubleshooting strategies for robust, reproducible results.

• Targeted Amikacin Sulfate Delivery: A New Era for NTM Therap

  2026-06-09

  This article provides translational researchers with an in-depth, evidence-backed roadmap for leveraging Amikacin Sulfate in advanced non-tuberculous mycobacterial infection models. It synthesizes mechanistic insights, pivotal in vivo findings, and strategic considerations, with actionable guidance on protocol design and the translational potential of dendritic cell-mediated delivery.

• Pazopanib (GW-786034): Translational Insights for Targeted C

  2026-06-09

  Explore the advanced mechanisms and translational applications of Pazopanib (GW-786034) in cancer research. Discover unique insights into ATRX-deficient tumor models and practical assay optimization, setting this resource apart from standard protocol guides.

• Anlotinib Hydrochloride: Redefining Multi-Target Angiogenesi

  2026-06-08

  Explore how Anlotinib hydrochloride, a next-generation multi-target tyrosine kinase inhibitor, is revolutionizing translational cancer research by combining precise ERK pathway inhibition with superior selectivity in endothelial cell migration and capillary tube formation assays. This thought-leadership article bridges mechanistic insight, competitive benchmarking, and actionable protocol guidance to empower researchers seeking robust, reproducible anti-angiogenic strategies.

• Dual Metrics in In Vitro Drug Response: Insights for Cancer

  2026-06-08

  Schwartz's dissertation advances in vitro cancer pharmacology by dissecting the relationship between proliferative arrest and cell death in drug response assays. Her work clarifies why dual-metric evaluation is essential for mechanistic insight and more predictive preclinical modeling, with implications for multikinase inhibitor research.

• Targeted EPO mRNA Nanoparticles Suppress Ferroptosis in SCI

  2026-06-07

  A recent study introduces mannose-modified lipid nanoparticles for precise delivery of human erythropoietin mRNA to inflammatory macrophages in spinal cord injury. This strategy enhances local EPO protein expression, suppresses ferroptosis, and significantly improves neuroprotection and functional recovery in preclinical models.

• Amiloride (MK-870): Unlocking Ion Channel Modulation for Tra

  2026-06-06

  Amiloride (MK-870), a dual ENaC and uPAR inhibitor, is redefining the landscape of sodium channel and cellular endocytosis research. This article provides mechanistic clarity and strategic guidance for translational scientists, situating Amiloride at the intersection of ion transport modulation, disease modeling, and next-generation immunotherapy platforms.

• Foretinib (GSK1363089): Applied Workflows in Cancer Research

  2026-06-05

  Foretinib (GSK1363089) enables robust, nanomolar-precision inhibition of multiple oncogenic kinases, streamlining assays for tumor cell growth and metastasis. This guide translates best practices and troubleshooting tips into actionable workflows, supporting advanced in vitro and xenograft models for oncology research.

• Smad3 Inhibition Reduces ADAMTS-5 in Early Osteoarthritis

  2026-06-05

  Xiang et al. demonstrate that targeted inhibition of Smad3, using SIS3, downregulates ADAMTS-5 and upregulates miRNA-140 in early-stage osteoarthritis. These findings clarify a mechanistic link in cartilage degradation and offer a framework for future therapeutic exploration.

14583 records 1/973 page Next 12345 下5页 Last page